Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Debt Issuances: 2014-2017

Historic Long-Term Debt Issuances for Lineage Cell Therapeutics (LCTX) over the last 2 years, with Dec 2017 value amounting to $41,000.

  • Lineage Cell Therapeutics' Long-Term Debt Issuances fell 93.25% to $41,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $425,000, marking a year-over-year decrease of 76.70%. This contributed to the annual value of $425,000 for FY2017, which is 75.81% down from last year.
  • As of Q4 2017, Lineage Cell Therapeutics' Long-Term Debt Issuances stood at $41,000, which was down 51.76% from $85,000 recorded in Q3 2017.
  • Lineage Cell Therapeutics' Long-Term Debt Issuances' 5-year high stood at $1.0 million during Q2 2016, with a 5-year trough of $4,000 in Q4 2014.
  • Its 3-year average for Long-Term Debt Issuances is $281,125, with a median of $127,000 in 2016.
  • In the last 5 years, Lineage Cell Therapeutics' Long-Term Debt Issuances soared by 1,575.00% in 2015 and then slumped by 93.25% in 2017.
  • Over the past 4 years, Lineage Cell Therapeutics' Long-Term Debt Issuances (Quarterly) stood at $4,000 in 2014, then spiked by 1,575.00% to $67,000 in 2015, then spiked by 805.97% to $607,000 in 2016, then crashed by 93.25% to $41,000 in 2017.
  • Its last three reported values are $41,000 in Q4 2017, $85,000 for Q3 2017, and $176,000 during Q2 2017.